Share-based Payment Arrangement, Expense in USD of MiNK Therapeutics, Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MiNK Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2020 to Q3 2025.
  • MiNK Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $621K, a 29.7% decline year-over-year.
  • MiNK Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $2.48M, a 29.7% decline year-over-year.
  • MiNK Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2.84M, a 25.8% decline from 2023.
  • MiNK Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3.83M, a 26.5% increase from 2022.
  • MiNK Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.03M, a 73.5% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

MiNK Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $2.48M $621K -$262K -29.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-14
Q2 2025 $2.74M $897K +$53K +6.28% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $2.69M $571K -$154K -21.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 $2.84M $390K -$682K -63.6% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-18
Q3 2024 $3.52M $883K -$56K -5.96% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-14
Q2 2024 $3.58M $844K -$54K -6.01% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $3.63M $725K -$196K -21.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q4 2023 $3.83M $1.07M +$405K +60.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-18
Q3 2023 $3.43M $939K +$166K +21.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $3.26M $898K +$97K +12.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $3.16M $921K +$135K +17.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $3.03M $667K -$305 -0.05% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $3.03M $773K +$386K +99.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $2.64M $801K +$394K +96.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $2.25M $786K +$503K +178% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $1.75M $667K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 $387K +$377K +3502% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $407K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $283K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q3 2020 $10.8K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-29

MiNK Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.84M -$988K -25.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-18
2023 $3.83M +$803K +26.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-18
2022 $3.03M +$1.28M +73.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 $1.75M +$1.66M +1883% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 $88K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.